atorvastatin has been researched along with rifampin in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Acimovic, J; Belic, A; Bjorkhem, I; Kocjan, D; Korosec, T; Monostory, K; Pascussi, JM; Rozman, D; Seliskar, M; Szabo, P; Urleb, U | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Barton, P; Ismair, M; Jupp, R; Riley, RJ; Soars, MG | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Backman, JT; Luurila, H; Neuvonen, M; Neuvonen, PJ | 1 |
| Benet, LZ; Huang, Y; Lau, YY; Okochi, H | 2 |
| Kivistö, KT | 1 |
| Benet, LZ; Frassetto, L; Huang, Y; Lau, YY | 1 |
| Cía, M; Martínez, M; Otermin, I; Pereda, A; Rivero, M | 1 |
| de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA | 1 |
| Chen, BL; Chen, Y; Guo, D; He, YJ; Kirchheiner, J; Li, Z; Tan, ZR; Tu, JH; Xu, LY; Yu, BN; Zhang, W; Zhou, G; Zhou, HH | 1 |
| Srinivas, NR | 1 |
| Rao, N | 1 |
| Chang, JH; Cheong, J; Ly, J; Messick, K; Plise, E; Wright, M; Zhang, X | 1 |
| da Silva, MG; do Nascimento, DC; Duarte, RS; Ferreira, Jda S; Hacker, MA; Lara, FA; Lobato, LS; Monteiro, CP; Moraes, MO; Neumann, Ada S; Oliveira, DS; Pedrini, SC; Pereira, GM; Pessolani, MC; Ribeiro-Alves, M; Rosa, PS; Soares, CT | 1 |
| Zhang, T | 1 |
| Korzekwa, K; Kulkarni, P; Nagar, S | 1 |
| Hasegawa, T; Higashino, H; Kataoka, M; Minami, K; Mutaguchi, K; Tachihara, M; Togashi, K; Yamashita, S | 1 |
| Ando, O; Furihata, K; Kusuhara, H; Maeda, K; Nakayama, T; Sugiyama, Y; Takehara, I; Terashima, H; Watanabe, N; Yoshida, M; Yoshikado, T | 1 |
| Kirby, BJ; Nelson, C; Othman, AA; Shen, G; Watkins, TR; Weber, E; Xiao, D; Younis, I | 1 |
2 review(s) available for atorvastatin and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
2 trial(s) available for atorvastatin and rifampin
| Article | Year |
|---|---|
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pyrroles; Rifampin | 2005 |
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Atorvastatin; Bile; Binding, Competitive; Biological Transport; Cell Line; Cross-Over Studies; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intravenous; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pyrroles; Rifampin; Substrate Specificity; Tablets; Transfection | 2007 |
22 other study(ies) available for atorvastatin and rifampin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Inhibition of human sterol Δ7-reductase and other postlanosterol enzymes by LK-980, a novel inhibitor of cholesterol synthesis.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Cytochrome P-450 CYP3A; Hep G2 Cells; Hepatocytes; Humans; Lanosterol; Lipogenesis; Models, Biological; Oxidoreductases Acting on CH-CH Group Donors; Piperazines; Pyridines | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
Topics: Cell Line; Drug Discovery; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems.
Topics: Animals; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Liver; Male; Microsomes, Liver; Organic Anion Transporters; Pyrroles; Rats; Rats, Sprague-Dawley; Rifampin; Tissue Distribution | 2006 |
Comments on "Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems".
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Cytochrome P-450 CYP3A; Drug Interactions; Heptanoic Acids; Liver; Organic Anion Transporters; Pyrroles; Rats; Rifampin | 2006 |
Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
Topics: Administration, Oral; Animals; Antibiotics, Antitubercular; Atorvastatin; Biological Availability; Drug Interactions; Heptanoic Acids; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Intestinal Mucosa; Intestines; Liver; Male; Microsomes; Organic Anion Transporters; Pyrroles; Rats; Rats, Sprague-Dawley; Rifampin | 2006 |
[Musculoskeletal adverse effects of levofloxacin].
Topics: Anti-Bacterial Agents; Arthralgia; Arthritis; Arthritis, Infectious; Arthroplasty, Replacement, Knee; Atorvastatin; Combined Modality Therapy; Debridement; Diagnosis, Differential; Doxycycline; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Levofloxacin; Middle Aged; Ofloxacin; Postoperative Complications; Prosthesis-Related Infections; Pyrroles; Recurrence; Reoperation; Rifampin; Thyroiditis, Autoimmune; Thyroxine; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Anticholesteremic Agents; Anticonvulsants; Antineoplastic Agents, Alkylating; Atorvastatin; Brain Neoplasms; Combined Modality Therapy; Cyclosporine; Dacarbazine; Dexamethasone; Female; Fluoxetine; Glioblastoma; Heptanoic Acids; Humans; Immunosuppressive Agents; Isoniazid; Middle Aged; Omeprazole; Phenobarbital; Prednisone; Pyrazinamide; Pyrroles; Radiotherapy; Red-Cell Aplasia, Pure; Rifampin; Temozolomide; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Pulmonary | 2009 |
Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
Topics: Atorvastatin; Genotype; Heptanoic Acids; Humans; Kinetics; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles; Rifampin; Thymidine; Young Adult | 2009 |
Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Purines; Pyrroles; Rifampin; Verapamil | 2009 |
Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Anion Transporters; Purines; Pyrroles; Research Design; Rifampin; Verapamil | 2011 |
Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice.
Topics: Animals; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; HEK293 Cells; Heptanoic Acids; Humans; Ketoconazole; Liver; Mice; Mice, Knockout; Organic Anion Transport Protein 1; Pyrroles; Rifampin | 2014 |
Statins increase rifampin mycobactericidal effect.
Topics: Animals; Antitubercular Agents; Atorvastatin; Cell Line; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leprosy; Macrophages; Mice; Mice, Inbred BALB C; Mycobacterium leprae; Mycobacterium tuberculosis; Pyrroles; Rifampin; Simvastatin | 2014 |
Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites.
Topics: Area Under Curve; Atorvastatin; Cimetidine; Clarithromycin; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Models, Biological; Phenytoin; Rifampin | 2015 |
Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.
Topics: Animals; Atorvastatin; Biological Transport; Cell Membrane; Diffusion; Intracellular Space; Liver; Male; Models, Biological; Rats; Rats, Sprague-Dawley; Rifampin; Triazoles | 2016 |
Quantitative Analysis of the Transporter-Mediated Drug-Drug Interaction Between Atorvastatin and Rifampicin Using a Stable Isotope-IV Method.
Topics: Administration, Oral; Animals; Atorvastatin; Biological Availability; Biological Transport; Dose-Response Relationship, Drug; Drug Interactions; Humans; Isotopes; Liver-Specific Organic Anion Transporter 1; Male; Permeability; Precision Medicine; Rats; Rats, Sprague-Dawley; Rifampin | 2017 |
Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers.
Topics: Adult; Atorvastatin; Bile Acids and Salts; Chenodeoxycholic Acid; Drug Interactions; Glucuronides; Glycochenodeoxycholic Acid; HEK293 Cells; Hepatocytes; Humans; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters, Sodium-Dependent; Pioglitazone; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3; Symporters; Taurocholic Acid; Thiazolidinediones; Young Adult | 2017 |
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
Topics: Adult; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Membrane Transport Proteins; Neoplasm Proteins; Organic Anion Transporters; Pharmaceutical Preparations; Rifampin | 2023 |